GBI Biomanufacturing (GBI)

Based in the US, GBI Biomanufacturing (GBI), operates as a full-service contract development and manufacturing organization (CDMO) specializing in biologic therapeutics. Based in Plantation, the US and founded in 1992, GBI Biomanufacturing (GBI) operates as a full-service contract development and manufacturing organization (CDMO). The company specializes in the development, scale-up, manufacturing, and commercialization of complex biologic therapeutics. GBI was formerly known as Goodwin Biotechnology Inc.

GBI Biomanufacturing operates as a full-service biopharmaceutical contract development and manufacturing organization (CDMO). The company provides integrated services throughout the lifecycle of biotherapeutics, including development, manufacturing, and regulatory support. GBI’s core service offerings encompass a range of biopharmaceutical manufacturing processes, such as cGMP clinical and commercial manufacturing, analytical method development, Aseptic Fill & Finish, and bioconjugation, including the development of Antibody-Oligonucleotide Conjugates (AOCs). GBI caters to pharmaceutical and biotechnology companies globally, focusing particularly on markets in North America and Europe.

GBI Biomanufacturing's revenue generation is primarily structured around project-based contracts with clients in the biopharmaceutical sector. These engagements involve comprehensive development and manufacturing services tailored to meet the specific needs of each client’s project stage. The company facilitates revenue through structured agreements that may include milestone payments as projects progress, emphasizing quality and timeliness as critical components of service delivery. GBI operates on a B2B model, partnering directly with pharmaceutical and biotechnology companies to deliver essential services that facilitate the advancement of biotherapeutics into clinical and commercial stages.

The company plans to expand its service offerings and enhance its capabilities in biopharmaceutical manufacturing. Current initiatives include the development of new technologies and processes to improve efficiency and scalability in production.